Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast Cancer
In Partnership With:
Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.
Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.
The final overall analysis of the phase II study of abemaciclib, a CDK4/6 inhibitor, showed an overall survival of about 22 months.
This trial suggests that abemaciclib has significant single-agent activity. Additionally, this agent may improve progression-free survival when combined with hormone therapy such as fulvestrant (Faslodex), says Rugo.
